今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

马斯克薪酬方案获股东大会通过 下一个考验将是机器人出租车？

北京，2024年6月14日讯 知名特斯拉多头、未来基金管理合伙人加里·布莱克（Gary Black）表示，马斯克的560亿美元薪酬方案周四在特斯拉年度股东大会上获得股东批准，这不太可能再次被法院推翻。

布莱克在推特上表示，“我不认为特拉华州衡平法院法官麦考密克会试图再次推翻特斯拉股东的意愿，他们再次以3：1的优势批准了埃隆2018年的薪酬计划……”

**在股东大会上，**特斯拉股东批准了马斯克的薪酬方案，以及将特斯拉注册地从特拉华州迁至德克萨斯州的提案。

**布莱克表示，**有利的投票结果应该消除了马斯克离开特斯拉的任何担忧。他预计特斯拉股价将在未来几天反弹3-5%，之后投资者的注意力将回到该公司第二季度的交付量上，他预计第二季度的交付量将低于去年同期。

**然而，**他说，“不确定因素”将是8月8日进行的机器人出租车发布活动，这可能会使股价上涨或下跌，取决于特斯拉是否发布其全自动驾驶（FSD）软件的无监督版本，这将使汽车实现真正意义上的自动驾驶。

**“我们仍看多特斯拉，但不会过于得意，”**Black补充道。

以下是特斯拉机器人出租车的一些潜在亮点：

• 完全自动驾驶： 该车辆将能够在没有人类干预的情况下自主导航和行驶。
• 低成本： 特斯拉的目标是使该车辆比传统出租车更便宜。
• 大规模生产： 特斯拉计划每年生产数百万辆机器人出租车。

如果特斯拉能够成功推出其机器人出租车，这可能会对交通运输行业产生重大影响。 它有可能使叫车更方便、更便宜，并减少对人类司机的需求。

**然而，**也有一些潜在的挑战。例如，一些人担心自动驾驶汽车的安全问题。此外，机器人出租车的推出可能会导致失业，因为许多出租车司机将失去工作。

总体而言，特斯拉机器人出租车是一项具有巨大潜力的技术。如果特斯拉能够克服挑战并成功推出该车辆，这可能会对公司及其股东产生重大积极影响。

以下是一些可能影响特斯拉机器人出租车未来成功的因素：

• 技术成熟度： 特斯拉需要确保其自动驾驶技术足够可靠和安全。
• 监管环境： 各国政府需要制定允许自动驾驶汽车上路的法规。
• 消费者接受度： 公众需要接受自动驾驶汽车的概念。
• 竞争： 其他公司也在开发自动驾驶汽车技术。

投资者应密切关注上述因素，审慎判断特斯拉机器人出租车的未来成功前景。